Cytokinetics (CYTK)
NASDAQ: CYTK
· Real-Time Price · USD
33.75
-0.63 (-1.83%)
At close: Jun 16, 2025, 3:59 PM
33.78
0.09%
After-hours: Jun 16, 2025, 04:20 PM EDT
-1.83% (1D)
| Bid | 32.84 |
| Market Cap | 4.03B |
| Revenue (ttm) | 19.22M |
| Net Income (ttm) | -615.26M |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -6.38 |
| Forward PE | -6.56 |
| Analyst | Buy |
| Ask | 35.34 |
| Volume | 1,327,118 |
| Avg. Volume (20D) | 2,092,407 |
| Open | 34.63 |
| Previous Close | 34.38 |
| Day's Range | 32.84 - 34.72 |
| 52-Week Range | 29.31 - 61.38 |
| Beta | 0.59 |
About CYTK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYTK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-12.98%
Cytokinetics shares are trading lower after the co...
Unlock content with
Pro Subscription
1 month ago
+0.19%
Cytokinetics shares are trading lower after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.
